

Novant Pharmacy

1900 S. Hawthorne Road
Suite 201
Winston Salem, NC 27103
Phone: 336-718-4687

Inside this Issue:

New Transfer or Discharge/Readmit Orders

Nicotrol Inhaler

Formulary Reviews

Medication Use Policy Subcommittee Report

MASCOT Report

COAST Report

Medication Shortage Impact

Editorial Staff:

Michael Nnadi, PharmD, MHS
VP, Pharmacy Services

Charles Matheson, PharmD
Corporate Clinical Director

Charles Hartis, PharmD
Clinical Pharmacy Manager

Deanna Rattray, PharmD, BCPS
Clinical Pharmacy Manager

Catherine Sury, PharmD
PGY1 Resident-PHC

Amanda Edwards, PharmD
PGY1 Resident-FMC

Rachel Holland, PharmD
PGY1 Resident-FMC

Sahal Khoshhal, PharmD, MS
Administrative Resident-FMC

New Transfer & Discharge/Readmit Order Process

Elizabeth Rebo, PharmD

This process change is for TR facilities only

Often transfer or discharge/readmit orders are printed well before a patient is physically moved. In the meantime, new orders are often written. The transfer or discharge/readmit orders will not contain these new orders. There have been instances where the intent was to continue the orders written during this transition time, but because they were not on the transfer or discharge/readmit order form, these new orders were missed.

To address this issue, the following process has been developed. After the transfer or discharge/readmit orders are printed, all blank regular prescriber order forms will be removed from the chart. At that time, a lime-green colored order form entitled "Additional Transfer Discharge Readmit Order Sheet" will be placed on the chart. All orders for the patient should be transcribed onto this sheet. Upon move, the transfer or discharge/readmit order sheets will be scanned to pharmacy along with all of the Additional Transfer Discharge Readmit Order Sheets. These orders will continue upon transfer. For the discharge/readmit process, these orders will be reviewed with the new attending for re-order.

Removal of Nicotrol Inhaler from Formulary

Charles Matheson, PharmD



P&T has approved the removal of Nicotrol (nicotine) Inhalers from Novant Formulary. This measure is anticipated to solve problems associated with the Nicotrol Inhalers. Re-dispensing lost patient inhalers have caused a burden on cost and time for some facilities. Also, the inhalers require special disposal because they are exposed to patient saliva. There currently is no evidence to support the use of one form of nicotine replacement over another. Current options for smoking cessation on Novant formulary still include nicotine patches and nicotine gum.


Know 5ive
SAVE LIVES

Formulary Review: Hydantoin Class

Allison Gaddy, PharmD

The Hydantoin class of medications was reviewed for formulary consolidation. The following phenytoin formulations were approved for removal from formulary:

- Phenytoin sodium ER 30 mg capsules (low usage)
- Phenytoin sodium ER 300 mg capsules (Rx to use three 100 mg capsules)



Cyclobenzaprine (Amrix®) Automatic Therapeutic Interchange

Charles Hartis, PharmD

A new extended-release version of cyclobenzaprine (Amrix®) has been approved by the FDA. The following therapeutic interchange to the immediate release tablet was approved by Novant P&T:

Drug Ordered	Drug Dispensed
Cyclobenzaprine (Amrix) 15 mg PO once daily	Cyclobenzaprine 5 mg PO TID
Cyclobenzaprine (Amrix) 30 mg PO once daily	Cyclobenzaprine 10 mg PO TID

Corporate Order Set Team (COAST) Subcommittee Report

John Gardella, MD

The following order sets have been approved by COAST with a go-live date of 12/15/11:

- Echocardiography with Perflutren Contrast Agent
- Organ/Tissue Donation, Carolina Donor Services—Adult
- Organ/Tissue Donation, LifeShare of the Carolinas—Adult
- Nephrology, Admission—Adult
- Cardiac Catheterization—Pre Procedure
- Cardiac Catheterization/Percutaneous Coronary Intervention—Post Procedure
- Erythropoiesis stimulating agents (ESA), excludes hemodialysis—Adults/Pediatrics
- Seasonal Influenza Immunization—Pediatrics
- Chronic Obstructive Pulmonary Disease, Acute Exacerbation/Bronchiectasis—Adult
- Cystitis/Pyelonephritis—Adult
- Electrolyte Replacement Medical/Surgical—Adult
- Electrolyte Replacement Intermediate Care/Stepdown Unit—Adult




Thank you to COAST for all of your efforts!

Medication Use Policy Subcommittee

Kathryn Montanya, PharmD

The Medication Use Policy Subcommittee (MUPS) of Novant P&T met on December 9th, 2011. Novant P&T approved the following policies:

GWSM Policies	Plegisol Stock for Emergency Open-Heart Cases Enteral Medication Administration Medication Administration Guidelines for Selected Drugs
GCM Policies	Order Sets NH Non-Invasive Cardiology Echo with Perflutren Pre-Surgical Antibiotic Prophylaxis Hemodialysis SPR-GCM and Brunswick IV Medication Extravasation
RRMC Policies	Blanket Orders Hypertonic Saline 3%, Use of Aminoglycoside Orders, Pharmacy Involvement High Alert Medications Lidocaine, Prilocaine Use of Alteplase in the Clearance of Central Venous Catheters Medication Administration Patient Specific Information Self-Administered Medications
Clinical Nutrition Services	Nutrition Criteria



Medication Safety Subcommittee

Bridget DuMont, PharmD

The corporate medication safety committee (MASCOT) met on November 14, 2011. The following are highlights from the meeting:

- KMC is working on hospital wide mandatory nursing education about heparin and calculations. Once completed, the education will be shared at all facility MUSIC meetings for evaluation of need to implement at individual hospitals.
- Two updated abbreviations were approved for policy including “certified nutrition support dietician” and “central parenteral nutrition”
- Corporate Safety Initiative Updates:
 - **MAC Overrides:** All facilities have had tremendous improvements overall. All facilities are < 2% for patient overrides and ~2% for medication overrides.
 - **Anticoagulation:** The draft of the new corporate heparin order set was presented to the group. It was also presented at the Cardiology subcommittee for P&T. There is a nursing IPOC that is coming out shortly related to bleeding risks.
 - **Allergies:** A tool has been developed to audit for compliance with the Novant allergy policy that needs to be tested and a cover sheet developed to explain the audit for consistent communication across all facilities.

Medication Shortage Impact

Kathy Doub, PharmD

Critical drug shortages continuing to plague health providers. A list of medications on critical shortage now or possibly in the future are presented below. Other pharmaceutical companies have increased production of some injection products, including glycopyrrolate ondansetron, and famotidine. Some of the items that have recently been removed from the back-order list (but not totally resolved) include: L-cysteine, fentanyl, butorphanol, diltiazem Inj, cytarabine, doxorubicin, etoposide, idarubicin, taxol.

Critical Shortages

- Bupivacaine 0.25% Inj—1/31/12
- Calcium Gluconate 100 mL Inj—12/14/11
- Glycopyrrolate Inj—12/26/11
- Ketorolac 30 mg Inj—12/20/11
- Octreotide Inj—11/25/11
- Sufentanil Inj—12/21/11
- Xylocaine 2% with Epinephrine—12/31/11
- Granisetron Inj—12/31/11

- Midazolam Inj—12/31/11
- Morphine Sulfate 15 mg ER tabs—12/21/11
- Rocuronium Inj—12/30/11
- Vecuronium Inj—11/30/11
- Ranitidine Inj—11/15/11

Possible Future Problems

- Lorazepam
- Midazolam
- Oxycodone



Formulary Class Review Teams:

Medicine Team I: Andrea Fender, Lorie Poole, Deanna Rattray, Christina Roels

Medicine Team II: Lisa Brennan, Gwen Mitchell, Chue Lee, Kristine Vaden

Medicine Team III: Sara Shields, Lauren Gurganus, Michael Evans

Medicine Team IV: Brock Harris, Amy Holmes, Allison Gaddy, Cam Haskett, Randi Bridges

Surgery/Critical Care Team I: Sara Szafran, Susan Smith, Jackie Olin, Patricia Pinder

Surgery/Critical Care Team II: Jeremy Hodges, Susan Wilson, Laura Bruner, Kevin Morris

Infectious Disease Team: Charles Hartis, Susan Smith

Oncology Team: Christina Ciccarello

Pediatrics Team: Amy Holmes, Brock Harris, Shannon Williams

Cardiology Team: Laura Frantz, Ryan Kammer



P&T Spotlight

Laura Frantz, PharmD, BCPS

Laura has been at Presbyterian Hospital for almost 11 years (as of Jan 22, 2012), working as a Cardiology Clinical Specialist. Laura will soon be transitioning away from Cardiology and into Critical Care. Laura's hometown is Kingsport, TN. She attended pharmacy school at University of Tennessee. She completed her residency at the VA Medical Center in Memphis, TN. Laura and her husband, Sam, have two kids: Matthew (8) and Jacob (5). Her hobbies include traveling, spending time with family, going to the YMCA/working out, and reading.



January Events

ID Subcommittee—January 11th

Oncology Subcommittee—January 10th

Novant P&T—January 26th